Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

BACKGROUND: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. METHODS: Al...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMJ Open Respir Res
Main Authors: Lancaster, Lisa, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, King, Talmadge E, Lederer, David J, Lin, Zhengning, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, Noble, Paul W
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2016
Fag:
Interstitial Lung Disease
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://ncbi.nlm.nih.gov/pubmed/26835133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2015-000105
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker